Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY Study)
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study was to test the hypothesis that Paricalcitol, an active form of
vitamin D, improved endothelial function in stage 3-4 chronic kidney disease (CKD) patients.
A secondary aim of this trial was to study the relationship between endothelial function and
plasma/serum and genetic biomarkers of bone mineral disorders in CKD (BMD-CKD) and renin
angiotensin-aldosteron system (RAS) (angiotensin II and plasma renin activity).